Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair
- Program for Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, New York
Abstract
A stable transfectant (S2SN7) of p53-null SaOS-2 (human osteosarcoma) cells expressing wild-type p53 under the tight control of a tetracycline-responsive promoter was used to study the functional roles of p53 in cellular response to cisplatinum (CP). When cells were grown in media containing normal concentrations (10%) of serum, induction of p53 by tetracycline withdrawal resulted in an 8-fold decrease in sensitivity to CP. In contrast, when cells were grown in lower serum (1%) media, induction of p53 led to a 10-fold increase in sensitivity to CP. The p53-mediated sensitivity to CP under lower serum conditions was attributed, at least in part, to increased susceptibility of p53-mediated apoptosis. Under lower serum (0.1–1%) but not normal serum conditions, p53 induction correlated with selective down-regulation of bcl-2, an inhibitor of apoptosis. In addition, a host-cell reactivation assay showed that induction of p53 caused a significant increase in repair of CP-induced DNA damage under normal serum but not low serum conditions. These data suggest that growth conditions may modulate and possibly reverse p53-mediated CP sensitivity by altering p53-mediated gene regulation and, as a result, susceptibility to apoptosis. They also suggest that a combined effect of p53-mediated apoptosis and DNA repair may be the ultimate determinant in p53-mediated cellular resistance or sensitivity to chemotherapeutic drugs.
Footnotes
-
Send reprint requests to: Dr. Joseph R. Bertino, Molecular Pharmacology and Therapeutics, Box 78, Sloan-Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10021. E-mail:bertino{at}mskcc.org
-
↵1 Supported by U.S. Public Health Service Training Grant CA62948-02.
-
This study was supported by U.S. Public Health Service (Grant PO1-CA-47179).
- Abbreviations:
- Tet
- tetracycline
- CAT
- chloramphenicol transferase
- FBS
- fetal bovine serum
- PBS
- phosphate buffered saline
- PCR
- polymerase chain reaction
- IC50
- concentration of drug that is responsible for 50% of cell kill
- CP
- cisplatinum
-
- Received April 6, 1999.
- Accepted July 16, 1999.
- The American Society for Pharmacology and Experimental Therapeutics



